Skip to main content
All lobbying filings

ASTELLAS PHARMA US, INC.

Lobbying for ASTELLAS PHARMA US, INC.

 Filing 3rd Quarter - Report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Expenses
$850,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Illinois

Official filing document

 Government bodies contacted 4
  • Centers For Medicare and Medicaid Services (CMS)
  • HOUSE OF REPRESENTATIVES
  • Natl Institutes of Health (NIH)
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
 Lobbying activity 4
Taxation/Internal Revenue Code

Issues related to OBBA (Pub. L. No: 119-21).

Medicare/Medicaid

Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).

Health Issues

H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.

Copyright/Patent/Trademark

Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem